Pre-made Tisotumab benchmark antibody ( Whole mAb, anti-F3 therapeutic antibody, Anti-CD142/TF/TFA Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-582

Pre-Made Tisotumab biosimilar, Whole mAb, Anti-F3 Antibody: Anti-CD142/TF/TFA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate or ADC targeted to Tissue Factor (TF), a protein involved in tumor signaling and angiogenesis.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-582-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Tisotumab biosimilar, Whole mAb, Anti-F3 Antibody: Anti-CD142/TF/TFA therapeutic antibody
INN Name Tisotumab
TargetF3
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesGenmab;Seattle Genetics
Conditions Approvedna
Conditions ActiveBladder cancer;Cervical cancer;Endometrial cancer;Fallopian tube cancer;Oesophageal cancer;Ovarian cancer;Peritoneal cancer;Prostate cancer;Solid tumours
Conditions Discontinuedna
Development Techna